CRESCENT BIOPHARMA INC (CBIO) Stock Analyst Ratings
USA - NASDAQ:CBIO - KYG2545C1042 - Common Stock
13.05 USD
-0.2 (-1.51%)
13.21 USD
+0.16 (+1.23%)
ChartMill assigns a Buy % Consensus number of 86% to CBIO. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 26.01. This target is 99.31% above the current price.
CBIO was analyzed by 13 analysts. The buy percentage consensus is at 86. So analysts seem to be very confident about CBIO.
In the previous month the buy percentage consensus was at a similar level.
CBIO was analyzed by 13 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-08-27 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-08-25 | Jefferies | Initiate | Buy |
| 2025-08-11 | HC Wainwright & Co. | Initiate | Buy |
| 2025-07-14 | Wedbush | Initiate | Outperform |
| 2025-06-25 | Stifel | Initiate | Buy |
| 2025-06-18 | LifeSci Capital | Initiate | Outperform |
| 2021-11-15 | Raymond James | Downgrade | Outperform -> Market Perform |
| 2021-08-06 | Raymond James | Maintains | Outperform |
| 2021-04-29 | Raymond James | Maintains | Outperform |
| 2021-02-10 | Piper Sandler | Initiate | Overweight |
CRESCENT BIOPHARMA INC / CBIO FAQ
What do analysts expect the price target to be for CRESCENT BIOPHARMA INC (CBIO)?
13 analysts have analysed CBIO and the average price target is 26.01 USD. This implies a price increase of 99.31% is expected in the next year compared to the current price of 13.05.
How do analysts rate CRESCENT BIOPHARMA INC (CBIO)?
The consensus rating for CRESCENT BIOPHARMA INC (CBIO) is 86.1538 / 100 . This indicates that analysts generally have a positive outlook on the stock.
Can you provide the analyst count for CRESCENT BIOPHARMA INC stock?
The number of analysts covering CRESCENT BIOPHARMA INC (CBIO) is 13.